Insights

Briefings for the people who sign off on healthcare AI

What changed in the rules, how to judge a category of vendor before anyone books a demo, and how a rollout is actually run once the contract is signed. Every piece is written by a consultant and reviewed before it goes up. Start with the group that matches the question you came with.

Regulatory change

What moved in the rules, and what it asks of a provider.

Buyer guides

How to evaluate a category before anyone books a demo.

Playbooks

How the work is actually run, step by step.

Analysis

Where the market is going, and which claims stopped being true.

Find the piece for where you are

Most readers land here with a specific job in front of them, not a craving for the newest post. Pick the paragraph that matches it.

Choosing: nothing is signed yet

The job is separating a vendor from its demo. Fifteen security and compliance questions belong in any RFP for a tool that will touch protected health information, and a shorter checklist for a scribe vendor specifically narrows that list to what should already be documented before the call. Running fewer than ten providers changes the answer: buying at that size means the self-serve end of the market and a monthly term, not an enterprise sales process built for a health system. the integration questions that decide the timeline cover which API a vendor actually uses to read and write, which is the detail that turns a two week go-live into a two month one. And before any of that, the build-versus-buy math names the narrow set of organisations for whom building is genuinely the right call.

Deploying: the contract is signed

Define the metrics before the pilot starts, not after: a baseline held for two weeks, one outcome metric that would justify the spend, and a stopping rule written down while everyone is still being reasonable. Knowing whether the thing you bought is an agent, a copilot or plain automation matters at the same stage, because that distinction is what decides the controls the rollout needs, not the vendor’s marketing name for it. And once it is live, adoption is won or lost in the eight weeks after go-live, with a champion model and a note quality feedback loop doing more than a mandate ever does.

Governing: more than one tool is live

A governance committee earns its place by returning decisions on a clock: a written charter, a named decision owner, and risk tiers that give a low-stakes tool a lighter review than a high-stakes one. A smaller practice rarely needs a committee at all; a two-page acceptable use policy covers approved tools, what staff may never paste into an unapproved one, and who reviews AI-drafted output before it is used. On the regulatory side, a year-by-year account of what actually moved tracks ONC, CMS and FDA in one place, a comparison of the state AI laws with healthcare duties covers a group operating across state lines, and the CMS-0057-F provider checklist turns a rule that binds payers, not providers, into the handful of things a provider organisation should actually check this quarter.

Fixing something that already went wrong

Sometimes the question is not what to buy or how to run it, but why a live tool is not working, or why a number being quoted in a meeting does not hold up. Pilots rarely stall because the model was bad: integration work that got deferred, a baseline nobody captured, and no governance route from pilot to production do most of the damage. The evidence behind the documentation burden numbers is narrower than the marketing built on top of it, and this piece says exactly where the two studies carrying most of that weight stop supporting the claim.

How these briefings are put together

Every piece here is written by the same research team that maintains the use case, EHR and regulation pages on this site, against sources it names rather than a vendor’s own claims. Each post carries a list of the sources it draws on and the date it was last checked, the same discipline the rest of the site runs on.

We take no commission, referral fee or paid placement from any vendor named in these posts, and no comparison or ranking here is sponsored. Where the evidence for a claim is thinner than the marketing around it, the piece says so, rather than repeating a number nobody can source. The full commitment, and the route to flag something that needs correcting, is on our editorial policy page.